ÇѸ²´ëÇб³¼º½Éº´¿ø

¼­Áø¿ø ±³¼ö

jwseomd@hallym.or.kr
  • Áø·á°ú º´¸®°ú

Àü¹®Áø·áºÐ¾ß

ºñ´¢±âº´¸®, ½ÅÀ庴¸®, À̽ĺ´¸®, Æóº´¸®

ÀüÈ­ ¿¹¾à 1577-1801
±³¼ö´Ô»çÁø

(ÁÖ°£) Áø·á½Ã°£Ç¥ (2025-01-13 ~ 2025-01-18)

Áø·á½Ã°£Ç¥
Áø·á½Ã°£ ¿ù È­ ¼ö ¸ñ ±Ý Åä
¿ÀÀü ÇØ´ç ÀÇ·áÁøÀÇ ÁöÁ¤µÈ ½ºÄÉÁìÀÌ ¾ø½À´Ï´Ù.
¿ÀÈÄ
±³¼ö´Ô »çÁø

±âº»Á¤º¸

ÇзÂ

ÇзÂ

2001.03 ~ 2003.02¼º±Õ°ü´ëÇб³ ÀÇÇÐ ¼®»ç

1993.03 ~ 1999.02´ë±¸°¡Å縯´ëÇб³ ÀÇÇÐ Çлç

°æ·Â

°æ·Â

2017.08 ~ ÇѸ²´ëÇб³¼º½Éº´¿ø º´¸®°ú ÀÓ»ó°úÀå

2008.03 ~ ÇѸ²´ëÇб³¼º½Éº´¿ø

2007.05 ~ 2008.02»ï¼º¼­¿ïº´¿ø ÀÓ»ó°­»ç

2000.03 ~ 2004.02»ï¼º¼­¿ïº´¿ø Àü°øÀÇ

ÇÐȸȰµ¿

ÇÐȸȰµ¿

´ëÇѺ´¸®ÇÐȸ

´ëÇѼ¼Æ÷º´¸®ÇÐȸ

³í¹®

Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma (DIAGNOSTIC PATHOLOGY)

Ultrasound and MRI Findings of Giant Cell Fibroblastoma in the Abdominal Wall: Radiologic-Pathologic Correlations / º¹º®¿¡ ¹ß»ýÇÑ °Å´ë¼¼Æ÷ ¼¶À¯¾Æ¼¼Æ÷Á¾ÀÇ ÃÊÀ½ÆÄ¿Í ÀÚ±â°ø¸í¿µ»ó ¼Ò°ß: ¿µ»ó¼Ò°ß°ú º´¸®ÇÐÀû ¼Ò°ßÀÇ ºñ±³ (´ëÇÑ¿µ»óÀÇÇÐȸÁö)

BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis (Pathology Research and Practice)

Targeted next-generation sequencing of well-differentiated rectal, gastric, and appendiceal neuroendocrine tumors to identify potential targets (HUMAN PATHOLOGY)

Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in ALK-positive lung cancer: Comparison with EGFR-mutated lung cancer (Pathology Research and Practice)

Treatment for gastric 'indefinite for neoplasm/dysplasia' lesions based on predictive factors (WORLD JOURNAL OF GASTROENTEROLOGY)

Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations (BMC CANCER)

Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-Line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer (CANCER RESEARCH AND TREATMENT)

Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition (HUMAN PATHOLOGY)

Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11 (GASTRIC CANCER)